Landscape Capital Management L.L.C. acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 19,340 shares of the biotechnology company’s stock, valued at approximately $1,052,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Exelixis by 0.5% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after acquiring an additional 281 shares during the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Exelixis by 5.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 5,406 shares of the biotechnology company’s stock valued at $237,000 after purchasing an additional 298 shares in the last quarter. Cim LLC increased its stake in Exelixis by 0.9% during the 3rd quarter. Cim LLC now owns 35,397 shares of the biotechnology company’s stock worth $1,462,000 after buying an additional 305 shares during the period. J.W. Cole Advisors Inc. increased its stake in Exelixis by 6.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 5,354 shares of the biotechnology company’s stock worth $235,000 after buying an additional 329 shares during the period. Finally, Fifth Third Wealth Advisors LLC lifted its holdings in Exelixis by 3.8% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 9,077 shares of the biotechnology company’s stock worth $389,000 after buying an additional 333 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.
Insiders Place Their Bets
In other Exelixis news, Director Mary C. Beckerle sold 9,812 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sue Gail Eckhardt sold 9,812 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $50.14, for a total transaction of $491,973.68. Following the sale, the director owned 16,079 shares of the company’s stock, valued at $806,201.06. This represents a 37.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 67,000 shares of company stock valued at $3,404,652. 2.60% of the stock is owned by company insiders.
Analysts Set New Price Targets
Exelixis Stock Performance
NASDAQ:EXEL opened at $54.08 on Monday. The stock has a 50-day simple moving average of $54.26 and a 200-day simple moving average of $48.60. The stock has a market cap of $13.40 billion, a P/E ratio of 17.01, a P/E/G ratio of 1.61 and a beta of 0.44. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $57.57.
Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The business had revenue of $628.69 million for the quarter, compared to the consensus estimate of $636.40 million. During the same quarter in the prior year, the business posted $0.75 EPS. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, equities research analysts predict that Exelixis, Inc. will post 3.18 EPS for the current year.
About Exelixis
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
See Also
- Five stocks we like better than Exelixis
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
